E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hormonal oral contraception in healthy women |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
• To evaluate the effects on hemostasis of NOMAC-E2 compared to LNG-EE. • To evaluate the effects on lipids and carbohydrate metabolism of NOMAC-E2 compared to LNG-EE. • To evaluate the effects on adrenal and thyroid function of NOMAC-E2 compared to LNG-EE.
|
|
E.2.2 | Secondary objectives of the trial |
• To collect data on contraceptive efficacy, cycle control and safety of NOMAC-E2 compared to LNG-EE. • To evaluate the effects on androgen levels of NOMAC-E2 compared to LNG-EE.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Sexually active women, at risk for pregnancy and not planning to use condoms during trial medication use; • Women in need for contraception and willing to use an OC for 6 months (6 cycles); • At least 18 but not older than 50 years of age at the time of screening; • Body mass index ≥17 and ≤29 kg/m2; • Good physical and mental health; • Willing to give informed consent in writing.
|
|
E.4 | Principal exclusion criteria |
• Present use or use within 2 months prior to screening of any other hormonal treatment including sex hormones (other than contraceptives), insulin, thyroid and corticosteroid hormones (with the exception for local dermatological use); • Contraindications for contraceptive steroids: - Presence or a history of venous or arterial thrombotic/thromboembolic events (e.g. deep venous thrombosis, pulmonary embolism, myocardial infarction) or of a cerebrovascular accident; - Presence or history of prodromi of a thrombosis (e.g. transient ischaemic attack, angina pectoris); - History of migraine with focal neurological symptoms; - Diabetes mellitus with vascular involvement; - The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis (to be judged by the (sub)-investigator). e.g. increasing age; smoking (with heavier smoking and increasing age the risk further increases, especially in women over 35 years of age); a positive family history (i.e. venous or arterial thromboembolism ever in a sibling or parent at a relatively early age); obesity (body mass index over 30 kg/m2); dyslipoproteinaemia; hypertension, migraine, valvular heart disease, atrial fibrillation; prolonged immobilization, major surgery, any surgery to the legs, or major trauma until two weeks after full remobilization; systemic lupus erythematosus; haemolytic uraemic syndrome; chronic inflammatory bowel disease (Crohn’s disease or ulcerative colitis); sickle cell disease; - Severe dyslipoproteinemia; - Severe hypertension; - Hereditary or acquired predisposition for venous or arterial thrombosis, such as APC resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia and antiphospholipidantibodies (anticardiolipin-antibodies, lupus anticoagulant); - Pancreatitis or a history thereof if associated with severe hypertriglyceridaemia; - Presence or history of severe hepatic disease as long as liver function values have not returned to normal; - Presence or history of liver tumors (benign or malignant); - Known or suspected sex steroid-influenced malignancies (e.g. of the genital organs or the breasts); - Undiagnosed vaginal bleeding; - Known or suspected pregnancy; - Hypersensitivity to the active substances or to any of the excipients of the investigational or comparator product. • Presence or history (within 1 year before screening) of alcohol or drug abuse as judged by the (sub)investigator; • An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia (CIN), SIL, carcinoma in situ, invasive carcinoma) at screening or documentation of an abnormal smear performed within 6 months before screening; • Clinically relevant abnormal laboratory result at screening as judged by the (sub)investigator; • Use of an injectable hormonal method of contraception prior to screening; within 6 months of an injection with a 3-month duration, within 4 months to screening of an injection with a 2-month duration, within 2 months of an injection with a 1-month duration; • Before spontaneous menstruation has occurred following a delivery or abortion; • Breastfeeding or within 2 months after stopping breastfeeding prior to the start of trial medication; • Present use or use within 2 months prior to the start of the trial medication of the following drugs: phenytoin, barbiturates, primidone, carbamazapine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, lipid-lowering drugs, anticoagulants and herbal remedies containing Hypericum perforatum (St John’s Wort); • Use of pharmacological agents which affect the hemostatic system during the pre-treatment blood sampling: vitamin K (only prohibited within two weeks prior to sampling), nonsteroidal anti-inflammatory drugs (NSAIDS) and aspirin (both only prohibited during the week prior to sampling); • Administration of investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Hemostatis parameters, lipids and carbohydrate metabolism parameters, adrenal and thyroid function parameters. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The date of the last assessment of the last patient undergoing the trial. Pregnancy follow-up may continue after the end of the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 3 |